# Submission rejected

## DRAFT REJECTED

**SPAR verdict:** `reject_critical` (3-0 unanimous reject).

## Proposed thesis (rejected)

> 48 adverse events occurred in 16 (84%) of 19 participants who received metformin and 48 adverse events occurred in 19 (90%) of 21 participants who received placebo.

## Failed citation traces

- **alias_match** on `C059` (ref=0): alias 'PhenoAge' NOT resolved (drift)

## Panel reviews

### `evidence_auditor` — `reject` (score 3)

Claim C059 failed its alias trace. The term 'PhenoAge' was not resolved, indicating a drift between the claim's terminology and the source evidence. According to the audit guidelines, any failed trace is grounds for rejection.

**Flagged claims:** C059

### `domain_skeptic` — `reject` (score 3)

The submission presents data from a study with an extremely small sample size (n=40 total), yet frames these results as 'moderate' evidence. From a domain perspective, a trial with only 19 participants in the treatment arm is severely underpowered to draw any meaningful conclusions about safety or efficacy, particularly regarding adverse events and biological aging markers. The reporting of '48 adverse events' in both groups is statistically trivial given the sample size and does not provide a robust safety profile.

Furthermore, there is a significant issue with 'off-topic drift' regarding the primary endpoint. The citation trace explicitly fails to resolve the alias 'PhenoAge', meaning the submission is attributing a specific numerical result to a biological age clock that the evidence may not actually be measuring or defining. This lack of conceptual alignment, combined with the negligible sample size, makes the claims over-scoped and scientifically unreliable.

**Flagged claims:** C059, C060

### `final_judge` — `reject` (score 3)

I align with both the Evidence Auditor and the Domain Skeptic. The failure of the alias trace for 'PhenoAge' in C059 is a critical technical failure; the submission attributes a specific numerical result to a metric that the citation trace could not verify as being present or defined in the source. This creates a gap in the evidence chain that cannot be ignored.

Furthermore, I find the Domain Skeptic's concerns regarding the sample size (n=40) highly persuasive. While the numbers may be accurately transcribed from the source, presenting results from such a severely underpowered study as 'moderate' evidence is misleading. The symmetry of the adverse event counts (48 in both groups) in such a small cohort is statistically unremarkable and does not support a robust safety conclusion. The combination of technical drift and scientific insignificance necessitates a rejection.

**Flagged claims:** C059, C060

## References

[27] Metformin and epigenetic age in non-diabetic older people with HIV in Madrid (METFORAGING): a double-blind, randomised, placebo-controlled, pilot trial. (2026). https://doi.org/10.1016/j.eclinm.2026.103874
